

3. Davies KM, Anselmi C, Wittig I, Faraldo-Gómez JD, Kühlbrandt W: Structure of the yeast F1Fo-ATP synthase dimer and its role in shaping the mitochondrial cristae. *Proc Natl Acad Sci U S A* 109: 13602–13607, 2012
4. Kaasik A, Safiulina D, Zharkovsky A, Veksler V: Regulation of mitochondrial matrix volume. *Am J Physiol Cell Physiol* 292: C157–C163, 2007
5. Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IE, Van 't Veer-Korthof ET, Van der Harten JJ, Sobotka-Plojhar MA: An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. *J Neurol Sci* 62: 327–355, 1983
6. Wiswedel I, Gardemann A, Storch A, Peter D, Schild L: Degradation of phospholipids by oxidative stress—exceptional significance of cardiolipin. *Free Radic Res* 44: 135–145, 2010
7. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M, Glick GD, Petronilli V, Zoratti M, Szabó I, Lippe G, Bernardi P: Dimers of mitochondrial ATP synthase form the permeability transition pore. *Proc Natl Acad Sci U S A* 110: 5887–5892, 2013
8. Hall AM, Rhodes GJ, Sandoval RM, Corridon PR, Molitoris BA: In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injury. *Kidney Int* 83: 72–83, 2013
9. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I: Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. *Proc Natl Acad Sci U S A* 97: 2826–2831, 2000
10. Brooks C, Wei Q, Cho SG, Dong Z: Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. *J Clin Invest* 119: 1275–1285, 2009
11. Plotnikov EY, Kazachenko AV, Vyssokikh MY, Vasileva AK, Tcvirkun DV, Isaev NK, Kirpatovsky VI, Zorov DB: The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. *Kidney Int* 72: 1493–1502, 2007
12. Cabral PD, Garvin JL: Luminal flow regulates NO and O₂(-) along the nephron. *Am J Physiol Renal Physiol* 300: F1047–F1053, 2011
13. Mitchell T, Rotaru D, Saba H, Smith RA, Murphy MP, MacMillan-Crow LA: The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renal tubular cells and rat kidneys. *J Pharmacol Exp Ther* 336: 682–692, 2011
14. Plotnikov EY, Chupyrkina AA, Jankauskas SS, Pevzner IB, Silachev DN, Skulachev VP, Zorov DB: Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. *Biochim Biophys Acta* 1812: 77–86, 2011
15. Szeto HH, Schiller PW: Novel therapies targeting inner mitochondrial membrane—from discovery to clinical development. *Pharm Res* 28: 2669–2679, 2011
16. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH: Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. *J Biol Chem* 279: 34682–34690, 2004
17. Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK: Potent mitochondria-targeted peptides reduce myocardial infarction in rats. *Coron Artery Dis* 18: 215–220, 2007
18. Szeto HH, Liu S, Soong Y, Wu D, Darrach SF, Cheng FY, Zhao Z, Ganger M, Tow CY, Seshan SV: Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. *J Am Soc Nephrol* 22: 1041–1052, 2011
19. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH: The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. *J Am Soc Nephrol* 24: 1250–1261, 2013
20. Hall AM, Crawford C, Unwin RJ, Duchon MR, Peppiatt-Wildman CM: Multiphoton imaging of the functioning kidney. *J Am Soc Nephrol* 22: 1297–1304, 2011
21. Cochemé HM, Quin C, McQuaker SJ, Cabreiro F, Logan A, Prime TA, Abakumova I, Patel JV, Fearnley IM, James AM, Porteous CM, Smith RA, Saeed S, Carré JE, Singer M, Gems D, Hartley RC, Partridge L, Murphy MP: Measurement of H₂O₂ within living *Drosophila* during aging using a ratiometric mass spectrometry probe targeted to the mitochondrial matrix. *Cell Metab* 13: 340–350, 2011
22. Murphy MP: How mitochondria produce reactive oxygen species. *Biochem J* 417: 1–13, 2009
23. Guzy RD, Schumacker PT: Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. *Exp Physiol* 91: 807–819, 2006
24. Parekh DJ, Weinberg JM, Ercole B, Torkko KC, Hilton W, Bennett M, Devarajan P, Venkatachalam MA: Tolerance of the human kidney to isolated controlled ischemia. *J Am Soc Nephrol* 24: 506–517, 2013
25. Castaneda MP, Swiatecka-Urban A, Mitsnefes MM, Feuerstein D, Kaskel FJ, Tellis V, Devarajan P: Activation of mitochondrial apoptotic pathways in human renal allografts after ischemiareperfusion injury. *Transplantation* 76: 50–54, 2003

See related article, “The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin,” on pages 1250–1261.

Vascular Access for Hemodialysis in Older Adults: A “Patient First” Approach

Ann M. O'Hare

Veterans Affairs Puget Sound Healthcare System, University of Washington, Seattle, Washington

J Am Soc Nephrol 24: 1187–1190, 2013.
doi: 10.1681/ASN.2013050507

In their landmark 1996 paper in *JAMA*, Hirth and colleagues reported that most patients in the United States with permanent vascular access were undergoing dialysis *via* a prosthetic graft rather than an autogenous fistula, despite known higher rates of infection and thrombosis associated with grafts.¹ These authors also reported large regional differences in rates of graft use—ranging from 23% of patients with a permanent access in New England to 85% in the East South Central census region—that were not explained by variation in patient characteristics.

These observations served as a wake-up call to the renal community, which responded with a series of initiatives to increase fistula use.² In 1997, the Kidney Disease Outcomes Quality Initiative (KDOQI) published clinical practice guidelines for hemodialysis vascular access that strongly favored the use of fistulas over grafts. In 1998, the Health Care Financing Administration (now Centers for Medicare and Medicaid Services [CMS]) developed clinical performance measures for vascular access that included target fistula and catheter

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Ann M. O'Hare, Veterans Affairs Puget Sound Healthcare System, University of Washington, 1160 South Columbian Way, Seattle, WA 98108. Email: ann.ohare@va.gov

Copyright © 2013 by the American Society of Nephrology

rates. In 2003, CMS partnered with the ESRD networks to implement the Fistula First initiative, a continuous quality improvement initiative intended to translate KDOQI guidelines into clinical practice.

Collectively, these efforts have dramatically reshaped patterns of permanent access use in the United States. As a result, most patients with permanent access now undergo dialysis *via* an autogenous fistula.³ More recently, Fistula First has turned its attention toward reducing catheter use because it has become clear that policies to promote fistula use have not had the intended effect of reducing catheter reliance.^{3–6}

Despite the success of these initiatives in reducing rates of graft use among patients of all ages, some authors have questioned the appropriateness of a “fistula first” approach in older adults.^{7,8} Because the theoretical advantages of fistulas over grafts do not accrue immediately, there is concern that patients with more limited life expectancy may not survive long enough to reap the benefits of having a fistula.^{9,10} Although grafts require more procedures to maintain patency, fistulas require more procedures to establish patency, with the result that overall patency may not differ substantially between the two forms of permanent access.^{11,12} This may be an especially important consideration in older adults because of their more limited life expectancy and increased risk of failed fistula maturation.^{9,10,13} In this issue of *JASN*, DeSilva and colleagues provide new information relevant to this dialogue.¹⁴ These authors describe survival among patients age 67 years and older who initiated long-term dialysis from 2005 to 2008 as a function of the type of vascular access first placed. In contrast to several prior studies reporting higher mortality rates in patients with a graft versus those with a fistula at the time of initiation, mortality rates for members of this cohort whose first access was a graft were similar to those for patients whose first access was a fistula. This was especially true in patients age 80 years and older, among whom mortality did not significantly differ by type of first permanent access placed. As described in other studies, mortality rates among patients with catheters at onset of dialysis were much higher than for patients who had received a graft or a fistula, and this was true for all age groups. Overall, 43% of patients who had received a fistula as their initial form of permanent access initiated dialysis with a catheter compared with 25% of those who had received a graft. These findings add to a growing body of work questioning the wisdom of a “fistula first” approach in older adults and arguing for greater flexibility in choice of hemodialysis access.^{7–10,15,16}

A limitation of policies intended to optimize vascular access for hemodialysis in this country has been a failure to take into account the complexities and challenges of the illness experience of individual patients with CKD. Strategies focusing on preferred and least preferred forms of vascular access fail to recognize that the relative benefits and harms of each form of access are critically dependent on the characteristics, circumstances, prognosis, preferences, and goals of individual patients.^{9,10,15,16} Because of heterogeneity in life expectancy,

health status, health priorities, and illness experiences, no one approach to vascular access—whether “graft first,” “fistula first,” or “catheter last”—can be expected to meet the needs of all older adults with advanced kidney disease.^{7,9} Further, the traditional outcomes examined in studies of vascular access, such as survival, infection, hospitalization, and costs, may not be those that matter the most to individual patients. A qualitative study conducted among 13 Canadian hemodialysis patients who had elected to receive chronic dialysis *via* a catheter identified adverse personal or vicarious experience with a fistula related to cannulation, bleeding, time commitment, and/or appearance as factors driving this decision.¹⁷ Others expressed a desire to maintain the status quo even when they understood the risks associated with catheter use.

Because many older patients with severe reductions in estimated GFR never go on to initiate dialysis,¹⁵ efforts to secure a functional fistula by the time of initiation may require that some accept the harms of a procedure from which they may never benefit.^{16,17} And even in situations where fistula placement would clearly be beneficial, older adults with advanced kidney disease (who often have a variety of other health conditions) may need to prioritize other, more pressing health concerns over fistula placement.^{18,19} Patients may themselves be uncertain about whether they would want dialysis should the need arise and may be unwilling to undergo fistula or even graft placement when there are so many unknowns.²⁰ One of my own patients, who agonized over this decision, identified uncertainty about “what kind of shape [he] would be in” when dialysis was needed as a major barrier to fistula placement. By failing to situate discussions about vascular access in the wider context of downstream treatment decisions about dialysis and desired treatment intensity toward the end of life,²¹ we may overlook those concerns of greatest import to the patient and risk committing some patients to a cascade of unwanted and potentially harmful interventions.

The findings of this study—that among older adults approaching dialysis, initial choice of permanent access does not greatly affect survival after initiation, and that those who receive a graft are less likely than those who receive a fistula to require a catheter at initiation—provide useful insights that may help to guide clinical decision-making. However, these results should be interpreted with the following considerations in mind. First, this study evaluated only the association between type of access and mortality and did not include other outcomes that may shape clinical decisions about vascular access. Second, it is not at all clear whether the association between type of access and survival reported in some prior studies reflects a true treatment effect versus the effect of unmeasured confounding. Third, while the authors designed this study as an intention-to-treat analysis, the analyses presented here do not really replicate real-world clinical decision-making because they do not include patients who underwent permanent access placement but did not initiate dialysis.

In shifting our focus from the population to the individual patient to develop a more patient-centered approach to access

planning, metrics that capture information on type of access selected (e.g., rates of fistula, graft, and catheter placement) become less relevant than those that characterize the process of access selection and the extent to which this meets the needs of individual patients. Ideally, this process should accomplish several goals: allowing clinicians to appreciate the unique experience, perspective, and goals of individual patients; helping patients and their families to better understand available treatment options and associated risks and benefits; and ensuring that patients and clinicians have an opportunity to share in decisions about vascular access.^{22–24} Most helpful in supporting shared decisions about vascular access will be efforts to enhance communication and knowledge transfer between patients and clinicians²⁵ and to generate outcome data that provide patients and clinicians with realistic expectations about different treatment options.²⁶

To optimally meet patients' needs, the process of choosing an access will often need to be dynamic in order to accommodate changing circumstances, health status and preferences, and interdependence between different types of access.^{27,28} Input from patients and other stakeholders should also be integral to any efforts to advance the field. For example, interventions to promote timely fistula placement might benefit from a better understanding of barriers to and facilitators of timely placement from the perspectives of patients, families, and clinicians. Efforts to support a more flexible approach to access placement would benefit from a better understanding of what outcomes matter most to patients. Input from patients and other stakeholders should also be instrumental in prioritizing among the many possible research strategies and initiatives intended to improve outcomes related to vascular access.

To deliver care that is truly centered on the patient, we may ultimately need to set aside traditional metrics focusing on universal treatment targets (e.g., rates of fistula, graft, and catheter use) in favor of new ones focusing on the extent to which the process and outcomes of access selection support the goals and preferences of individual patients.²⁹

DISCLOSURES

A.M.O. is an employee of the United States federal government and receives an honorarium from UpToDate and grant support from the Department of Veterans Affairs, the National Institute on Aging, and the Centers for Disease Control and Prevention.

REFERENCES

- Hirth RA, Turenne MN, Woods JD, Young EW, Port FK, Pauly MV, Held PJ: Predictors of type of vascular access in hemodialysis patients. *JAMA* 276: 1303–1308, 1996
- Lok CE: Fistula first initiative: Advantages and pitfalls. *Clin J Am Soc Nephrol* 2: 1043–1053, 2007
- Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH, Spergel LM; Fistula First Breakthrough Initiative Community Education Committee: Fistula first breakthrough initiative: Targeting catheter last in fistula first. *Semin Dial* 25: 303–310, 2012
- Fulton JJ: Balancing 'fistula first' with a 'catheter last' strategy. *Nephrol News Issues* 23: 28–30, 2009
- Lacson E Jr, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM: Balancing fistula first with catheters last. *Am J Kidney Dis* 50: 379–395, 2007
- Hakim RM, Himmelfarb J: Hemodialysis access failure: A call to action—revisited. *Kidney Int* 76: 1040–1048, 2009
- Richardson AI 2nd, Leake A, Schmieder GC, Biuckians A, Stokes GK, Panneton JM, Glickman MH: Should fistulas really be first in the elderly patient? *J Vasc Access* 10: 199–202, 2009
- Vachharajani TJ, Moossavi S, Jordan JR, Vachharajani V, Freedman BI, Burkart JM: Re-evaluating the Fistula First initiative in octogenarians on hemodialysis. *Clin J Am Soc Nephrol* 6: 1663–1667, 2011
- Tamura MK, Tan JC, O'Hare AM: Optimizing renal replacement therapy in older adults: A framework for making individualized decisions. *Kidney Int* 82: 261–269, 2012
- Moist LM, Lok CE, Vachharajani TJ, Xi W, AlJaishi A, Polkinghorne KR, Vazquez M, Lee TC: Optimal hemodialysis vascular access in the elderly patient. *Semin Dial* 25: 640–648, 2012
- Lok CE, Sontrop JM, Tomlinson G, Rajan D, Cattral M, Oreopoulos G, Harris J, Moist L: Cumulative patency of contemporary fistulas versus grafts (2000–2010). *Clin J Am Soc Nephrol* 8: 810–818, 2013
- Lok CE, Oliver MJ, Su J, Bhola C, Hannigan N, Jassal SV: Arteriovenous fistula outcomes in the era of the elderly dialysis population. *Kidney Int* 67: 2462–2469, 2005
- Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D: Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). *J Am Soc Nephrol* 17: 3204–3212, 2006
- DeSilva RN, Patibandla BK, Vin Y, Narra A, Chawla V, Brown RS, Goldfarb-Rumyantsev AS: Fistula first is not always the best strategy for the elderly. *J Am Soc Nephrol* 24: 1297–1304, 2013
- O'Hare AM, Bertenthal D, Walter LC, Garg AX, Covinsky K, Kaufman JS, Rodriguez RA, Allon M: When to refer patients with chronic kidney disease for vascular access surgery: Should age be a consideration? *Kidney Int* 71: 555–561, 2007
- O'Hare AM, Allon M, Kaufman JS: Whether and when to refer patients for predialysis AV fistula creation: Complex decision making in the face of uncertainty. *Semin Dial* 23: 452–455, 2010
- Xi W, Harwood L, Diamant MJ, Brown JB, Gallo K, Sontrop JM, MacNab JJ, Moist LM: Patient attitudes towards the arteriovenous fistula: A qualitative study on vascular access decision making. *Nephrol Dial Transplant* 26: 3302–3308, 2011
- Bowling CB, O'Hare AM: Managing older adults with CKD: Individualized versus disease-based approaches. *Am J Kidney Dis* 59: 293–302, 2012
- Tinetti ME, Fried TR, Boyd CM: Designing health care for the most common chronic condition—multimorbidity. *JAMA* 307: 2493–2494, 2012
- Schell JO, Patel UD, Steinhilber KE, Ammarell N, Tulskey JA: Discussions of the kidney disease trajectory by elderly patients and nephrologists: A qualitative study. *Am J Kidney Dis* 59: 495–503, 2012
- Kaufman SR, Shim JK, Russ AJ: Old age, life extension, and the character of medical choice. *J Gerontol B Psychol Sci Soc Sci* 61: S175–S184, 2006
- Moist LM, Lee TC, Lok CE, Al-Jaishi A, Xi W, Campbell V, Graham J, Wilson B, Vachharajani TJ: Education in vascular access. *Semin Dial* 26: 148–153, 2013
- Moss AH: Revised dialysis clinical practice guideline promotes more informed decision-making. *Clin J Am Soc Nephrol* 5: 2380–2383, 2010
- Moss AH: Shared decision-making in dialysis: The new RPA/ASN guideline on appropriate initiation and withdrawal of treatment. *Am J Kidney Dis* 37: 1081–1091, 2001
- Schell JO, Arnold RM: NephroTalk: Communication tools to enhance patient-centered care. *Semin Dial* 25: 611–616, 2012
- Tinetti ME, Studenski SA: Comparative effectiveness research and patients with multiple chronic conditions. *N Engl J Med* 364: 2478–2481, 2011

27. Schell JO, O'Hare AM: Illness trajectories and their relevance to the care of adults with kidney disease [published online ahead of print March 20, 2013]. *Curr Opin Nephrol Hypertens* doi: 10.1097/MNH.0b013e32835ffaaf
28. Lok CE, Davidson I: Optimal choice of dialysis access for chronic kidney disease patients: Developing a life plan for dialysis access. *Semin Nephrol* 32: 530–537, 2012
29. Reuben DB, Tinetti ME: Goal-oriented patient care—an alternative health outcomes paradigm. *N Engl J Med* 366: 777–779, 2012

See related article, "Fistula First Is Not Always the Best Strategy for the Elderly," on pages 1297–1304.

Can Genetics Risk-Stratify Patients with Membranous Nephropathy?

Andrew S. Bomback and Ali G. Gharavi

Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York

J Am Soc Nephrol 24: 1190–1192, 2013.
doi: 10.1681/ASN.2013060576

Membranous nephropathy (MN) is the leading cause of primary nephrotic syndrome in white adults and a major cause of nephrotic syndrome across global populations. In MN, circulating antibodies permeate the glomerular basement membrane and, in the subepithelial space, form immune complexes with antigens on podocyte membranes. Recently, the M-type phospholipase A₂ receptor (PLA₂R) was identified as the specific podocyte antigen responsible for eliciting immune complex formation with circulating antibodies. Anti-PLA₂R antibodies are detected in 60%–75% of idiopathic MN cases across many ethnicities.^{1,2} Additional podocyte autoantigens—mitochondrial SOD 2, aldose reductase, α -enolase, and neutral endopeptidase^{3,4}—have likewise emerged as potential targets of MN-specific autoantibodies, potentially filling in the missing gaps in PLA₂R antibody-negative disease. These breakthroughs have established MN as a disease of autoantibodies and, in many ways, challenge the continued use of the term *idiopathic MN*.⁵ Nonetheless, we still do not know why, exactly, such autoantibodies develop in MN. The identified podocyte antigens are endogenously expressed; only the autoantibodies against such antigens are detected in patients with MN.

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Ali G. Gharavi, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, Russ Berrie Pavilion, Room 412, 1150 St. Nicholas Avenue, New York, NY 10032. Email: ag2239@columbia.edu

Copyright © 2013 by the American Society of Nephrology

Previous case reports of familial forms of MN have suggested a genetic predisposition to disease.⁶ In a recent genome-wide association study (GWAS) in three European populations (French, Dutch, and British), Stanescu *et al.* described associations of MN with the HLA locus on chromosome 6p21 and the *PLA2R1* locus (encoding PLA₂R) on chromosome 2q24.⁷ The association with HLA was significant in all three patient samples, whereas the association with *PLA2R1* was significant in the Dutch and British samples (as well as in joint analysis of all three populations). Strikingly, whereas the risk of disease was relatively modest in individuals with risk alleles at any one locus, the odds ratio for MN was an astronomical 78.5 (95% confidence interval [95% CI], 34.6 to 178.2) in individuals homozygous for risk alleles at both loci, indicative of strong genetic interaction. This GWAS was thus unusual because the effect sizes imparted by the combined risk alleles were very large, suggesting a potential role for genetics for noninvasive screening or risk stratification of MN. This study also provided an independent line of evidence implicating *PLA2R1* in the pathogenesis of disease, suggesting that sequence variants within *PLA2R1* may alter expression or function of PLA₂R, potentially unmasking it as an autoantigen that, in conjunction with the right MHC haplotype, results in activation of T cells and stimulation of autoantibody production. Limitations of this GWAS included the relatively small sample size, which precluded precise localization of the risk alleles within each locus. Particularly, the origin of the signal within the MHC locus remained unclear,⁸ because this region has a very complicated structure, and class I and class II response loci may each contain multiple independent haplotypes with opposing effects on risk of disease. These findings thus required follow-up in larger cohorts and validation beyond European populations.

In this issue of *JASN*, Lv and colleagues genotyped 1112 Chinese patients with MN and 1020 healthy controls for the top single-nucleotide polymorphism (SNPs) in the European GWAS (three SNPs within the *PLA2R1* locus and three SNPs within HLA genes).⁹ All three SNPs within *PLA2R1* were highly associated with MN, and the strongest signal emerged from the same SNP (rs4664308) identified in the European GWAS. The HLA-DQA1 SNP (rs2187668) also showed association with MN, whereas two other HLA-located SNPs showed no such association with disease. Thus, this study robustly replicated the genetic signal demonstrated in a GWAS of European cohorts. However, in this Chinese population, the odds ratio for MN associated with homozygosity for both risk alleles was 9.9 (95% CI, 1.1 to 91.9), which is much lower than the odds ratio described for Europeans. Interestingly, the odds ratio rose to 11.1 (95% CI, 6.5 to 19.2) when looking at patients homozygous for the *PLA2R1* risk allele but either homozygous or heterozygous for the HLA-DQA1 risk allele. Similar findings have been reported in replication studies from Korea¹⁰ and Taiwan¹¹; the lower odds ratio in Asians suggests true differences in effect size between different ethnicities but may also reflect convergence to the mean. Because